Update on antiretroviral treatment during primary HIV infection

References

• Lindback S, Karlsson AC, Mittler J, et al. Viral dynamics in primary HIV-1 infection. Karolinska Institutet Primary HIV Infection Study Group. AIDS 2000;14(15):2283-91
   PubMed Web of Science ®Google Scholar
• Miro JM, Sued O, Plana M, et al. [Advances in the diagnosis and treatment of acute human immunodeficiency virus type 1 (HIV-1) infection]. Enferm Infecc Microbiol Clin 2004;22(10):643-59
   PubMed Web of Science ®Google Scholar
• Fidler S, Fox J, Porter K, Weber J. Primary HIV infection: to treat or not to treat? Curr Opin Infect Dis 2008;21(1):4-10
   PubMed Web of Science ®Google Scholar
• Pilcher CD, Eron JJ Jr, Galvin S, et al. Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest 2004;113(7):937-45
   PubMed Web of Science ®Google Scholar
• Ambrosioni J, Calmy A, Hirschel B. HIV treatment for prevention. J Int AIDS Soc 2011;14:28
   PubMed Web of Science ®Google Scholar
• Ambrosioni J, Junier T, Delhumeau C, et al. Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections. AIDS 2012;26(16):2079-86
   PubMed Web of Science ®Google Scholar
• Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365(6):493-505
   PubMed Web of Science ®Google Scholar
• Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infection. N Engl J Med 2011;364(20):1943-54
   PubMed Web of Science ®Google Scholar
• Fox J, White PJ, Macdonald N, et al. Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men. HIV Med 2009;10(7):432-8
   PubMed Web of Science ®Google Scholar
• Rieder P, Joos B, von Wyl V, et al. HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS 2010;24(8):1177-83
   PubMed Web of Science ®Google Scholar
• Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010;24(10):1598-601
   PubMed Web of Science ®Google Scholar
• Hocqueloux L, Avettand-Fenoel V, Jacquot S, et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 2013;68(5):1169-78
   PubMed Web of Science ®Google Scholar
• Altfeld M, Rosenberg ES, Shankarappa R, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001;193(2):169-80
   PubMed Web of Science ®Google Scholar
• Cohen DE, Walker BD. Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection. Clin Infect Dis 2001;32(12):1756-68
   PubMed Web of Science ®Google Scholar
• Oxenius A, Yerly S, Ramirez E, et al. Distribution of functional HIV-specific CD8 T lymphocytes between blood and secondary lymphoid organs after 8-18 months of antiretroviral therapy in acutely infected patients. AIDS 2001;15(13):1653-6
   PubMed Web of Science ®Google Scholar
• Oxenius A, Fidler S, Brady M, et al. Variable fate of virus-specific CD4(+) T cells during primary HIV-1 infection. Eur J Immunol 2001;31(12):3782-8
   PubMed Web of Science ®Google Scholar
• Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407(6803):523-6
   PubMed Web of Science ®Google Scholar
• Lecuroux C, Girault I, Boutboul F, et al. Antiretroviral therapy initiation during primary HIV infection enhances both CD127 expression and the proliferative capacity of HIV-specific CD8+ T cells. AIDS 2009;23(13):1649-58
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Borrow P, Tomaras GD, et al. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010;10(1):11-23
   PubMed Web of Science ®Google Scholar
• Mehandru S, Poles MA, Tenner-Racz K, et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med 2006;3(12):e484
   PubMed Web of Science ®Google Scholar
• Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004;200(6):761-70
   PubMed Web of Science ®Google Scholar
• WHO. HIV/AIDS 2012 Global Report
   Google Scholar
• Caro-Murillo AM, Castilla J, Perez-Hoyos S, et al. [Spanish cohort of naive HIV-infected patients (CoRIS): rationale, organization and initial results]. Enferm Infecc Microbiol Clin 2007;25(1):23-31
   PubMed Web of Science ®Google Scholar
• Le VS, Le SY, Barin F, et al. Population-based HIV-1 incidence in France, 2003-08: a modelling analysis. Lancet Infect Dis 2010;10(10):682-7
   PubMed Web of Science ®Google Scholar
• Romero A, Gonzalez V, Granell M, et al. Recently acquired HIV infection in Spain (2003-2005): introduction of the serological testing algorithm for recent HIV seroconversion. Sex Transm Infect 2009;85(2):106-10
   PubMed Web of Science ®Google Scholar
• Romero A, Gonzalez V, Esteve A, et al. Identification of recent HIV-1 infection among newly diagnosed cases in Catalonia, Spain (2006-08). Eur J Public Health 2012;22(6):802-8
   PubMed Web of Science ®Google Scholar
• Lindback S, Thorstensson R, Karlsson AC, et al. Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group. AIDS 2000;14(15):2333-9
   PubMed Web of Science ®Google Scholar
• Harman AN, Kim M, Nasr N, et al. Tissue dendritic cells as portals for HIV entry. Rev Med Virol 2013;23(5):319-33
   PubMed Web of Science ®Google Scholar
• Fisher M, Pao D, Brown AE, et al. Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach. AIDS 2010;24(11):1739-47
   PubMed Web of Science ®Google Scholar
• Ragonnet-Cronin M, Ofner-Agostini M, Merks H, et al. Longitudinal phylogenetic surveillance identifies distinct patterns of cluster dynamics. J Acquir Immune Defic Syndr 2010;55(1):102-8
   PubMed Web of Science ®Google Scholar
• Yerly S, Junier T, Gayet-Ageron A, et al. The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS 2009;23(11):1415-23
   PubMed Web of Science ®Google Scholar
• Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 2007;59(6):1047-56
   PubMed Web of Science ®Google Scholar
• Girardi E. Epidemiological aspects of transmitted HIV drug resistance. Scand J Infect Dis Suppl 2003;106:17-20
   PubMedGoogle Scholar
• Yebra G, Holguin A. [Epidemiology of drug-resistant HIV-1 transmission in naive patients in Spain]. Med Clin (Barc) 2010;135(12):561-7
   PubMed Web of Science ®Google Scholar
• de Mendoza C, Rodriguez C, Colomina J, et al. Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin Infect Dis 2005;41(9):1350-4
   PubMed Web of Science ®Google Scholar
• Descamps D, Chaix ML, Andre P, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 2005;38(5):545-52
   PubMed Web of Science ®Google Scholar
• Violin M, Velleca R, Cozzi-Lepri A, et al. Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001. J Acquir Immune Defic Syndr 2004;36(2):761-4
   PubMed Web of Science ®Google Scholar
• De Gascun CF, Waters A, Regan C, et al. Documented prevalence of HIV type 1 antiretroviral transmitted drug resistance in Ireland from 2004 to 2008. AIDS Res Hum Retroviruses 2012;28(3):276-81
   PubMed Web of Science ®Google Scholar
• Monge S, Guillot V, Alvarez M, et al. Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class. Clin Microbiol Infect 2012;18(11):E485-90
   PubMed Web of Science ®Google Scholar
• Descamps D, Assoumou L, Chaix ML, et al. National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011. J Antimicrob Chemother 2013;68(11):2626-31
   PubMed Web of Science ®Google Scholar
• Karlsson A, Bjorkman P, Bratt G, et al. Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010. PLoS One 2012;7(3):e33484
   PubMed Web of Science ®Google Scholar
• Vercauteren J, Wensing AM, Van de Vijver DA, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009;200(10):1503-8
   PubMed Web of Science ®Google Scholar
• Wensing AM, Van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005;192(6):958-66
   PubMed Web of Science ®Google Scholar
• Wittkop L, Gunthard HF, de WF, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011;11(5):363-71
   PubMed Web of Science ®Google Scholar
• Smith D, Moini N, Pesano R, et al. Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection. Clin Infect Dis 2007;44(3):456-8
   PubMed Web of Science ®Google Scholar
• Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004;189(12):2174-80
   PubMed Web of Science ®Google Scholar
• Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347(6):385-94
   PubMed Web of Science ®Google Scholar
• Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 2010;24(8):1203-12
   PubMed Web of Science ®Google Scholar
• Kim D, Wheeler W, Ziebell R, et al. Prevalence of transmitted antiretroviral drug resistance among newly-diagnosed HIV-1-infected persons, US, 2007. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, 16-19 February 2010 (Paper #580)
   Google Scholar
• Tshabalala M, Manasa J, Zijenah LS, et al. Surveillance of transmitted antiretroviral drug resistance among HIV-1 infected women attending antenatal clinics in Chitungwiza, Zimbabwe. PLoS One 2011;6(6):e21241
   PubMed Web of Science ®Google Scholar
• Afonso JM, Bello G, Guimaraes ML, et al. HIV-1 genetic diversity and transmitted drug resistance mutations among patients from the North, Central and South regions of Angola. PLoS One 2012;7(8):e42996
   PubMed Web of Science ®Google Scholar
• Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011;11(10):750-9
   PubMed Web of Science ®Google Scholar
• WHO. WHO HIV Drug Resistance Report 2012. Available from: www.who.int/mediacentre/news/notes/2012/hiv_drug_resistance_20120718/en/index.html
   Google Scholar
• Hamers RL, Sigaloff KC, Kityo C, et al. Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. Curr Opin HIV AIDS 2013;8(1):19-26
   PubMed Web of Science ®Google Scholar
• Ferreira JL, Rodrigues R, Lanca AM, et al. Transmitted Drug Resistance among People Living with HIV/Aids at Major Cities of Sao Paulo State, Brazil. Adv Virol 2013;2013:878237
   PubMedGoogle Scholar
• Ávila-Ríos S, Garcia-Morales C, Garrido-Rodriguez D, et al. National prevalence and trends of HIV transmitted drug resistance in Mexico. PLoS One 2011;6(11):e27812
   PubMed Web of Science ®Google Scholar
• Yang J, Xing H, Niu J, et al. The emergence of HIV-1 primary drug resistance genotypes among treatment-naive men who have sex with men in high-prevalence areas in China. Arch Virol 2013;158(4):839-44
   PubMed Web of Science ®Google Scholar
• Sungkanuparph S, Sukasem C, Kiertiburanakul S, et al. Emergence of HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand. J Int AIDS Soc 2012;15(1):12
   PubMed Web of Science ®Google Scholar
• Hattori J, Shiino T, Gatanaga H, et al. Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan. Antiviral Res 2010;88(1):72-9
   PubMed Web of Science ®Google Scholar
• Lai CC, Hung CC, Chen MY, et al. Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan. J Antimicrob Chemother 2012;67(5):1254-60
   PubMed Web of Science ®Google Scholar
• Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003;17(13):1871-9
   PubMed Web of Science ®Google Scholar
• Ananworanich J, Fletcher JL, Pinyakorn S, et al. A novel acute HIV infection staging system based on 4th generation immunoassay. Retrovirology 2013;10:56
   PubMed Web of Science ®Google Scholar
• Mehandru S, Poles MA, Tenner-Racz K, et al. Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection. J Virol 2007;81(2):599-612
   PubMed Web of Science ®Google Scholar
• Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004;200(6):761-70
   PubMed Web of Science ®Google Scholar
• Mehandru S, Poles MA, Tenner-Racz K, et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med 2006;3(12):e484
   PubMed Web of Science ®Google Scholar
• Douek D. HIV disease progression: immune activation, microbes, and a leaky gut. Top HIV Med 2007;15(4):114-17
   PubMedGoogle Scholar
• Hamlyn E, Fidler S, Stohr W, et al. Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression. AIDS 2013;28(6):869-74
   Web of Science ®Google Scholar
• Leeansyah E, Malone DF, Anthony DD, Sandberg JK. Soluble biomarkers of HIV transmission, disease progression and comorbidities. Curr Opin HIV AIDS 2013;8(2):117-24
   PubMed Web of Science ®Google Scholar
• Lavreys L, Baeten JM, Chohan V, et al. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis 2006;42(9):1333-9
   PubMed Web of Science ®Google Scholar
• Socias ME, Sued O, Laufer N, et al. Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters. J Int AIDS Soc 2011;14:40
   PubMed Web of Science ®Google Scholar
• Goujard C, Bonarek M, Meyer L, et al. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 2006;42(5):709-15
   PubMed Web of Science ®Google Scholar
• Martinez-Picado J. Host-Virus interactions in HIV-1 rapid disease progression. AIDS Vaccine 2013; Barcelona, Spain, 7-10 October 2013 (Abstract S05-02)
   Google Scholar
• Frange P, Galimand J, Goujard C, et al. High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study. J Antimicrob Chemother 2009;64(1):135-41
   PubMed Web of Science ®Google Scholar
• Frange P, Meyer L, Ghosn J, et al. Prevalence of CXCR4-tropic viruses in clustered transmission chains at the time of primary HIV-1 infection. Clin Microbiol Infect 2013;19(5):E252-5
   PubMed Web of Science ®Google Scholar
• Chaix ML, Seng R, Frange P, et al. Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy. Clin Infect Dis 2013;56(6):880-7
   PubMed Web of Science ®Google Scholar
• Baker BM, Block BL, Rothchild AC, Walker BD. Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther 2009;9(1):55-69
   PubMed Web of Science ®Google Scholar
• Goujard C, Chaix ML, Lambotte O, et al. Spontaneous control of viral replication during primary HIV infection: when is “HIV controller” status established? Clin Infect Dis 2009;49(6):982-6
   PubMed Web of Science ®Google Scholar
• Fidler S, Porter K, Ewings F, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013;368(3):207-17
   PubMed Web of Science ®Google Scholar
• Streeck H, Jessen H, Alter G, et al. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis 2006;194(6):734-9
   PubMed Web of Science ®Google Scholar
• Markowitz M, Jin X, Hurley A, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002;186(5):634-43
   PubMed Web of Science ®Google Scholar
• Desquilbet L, Goujard C, Rouzioux C, et al. Does transient HAART during primary HIV-1 infection lower the virological set-point? AIDS 2004;18(18):2361-9
   PubMed Web of Science ®Google Scholar
• Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006;194(6):725-33
   PubMed Web of Science ®Google Scholar
• Steingrover R, Garcia EF, van Valkengoed IG, et al. Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection. AIDS Res Hum Retroviruses 2010;26(4):379-87
   PubMed Web of Science ®Google Scholar
• Koegl C, Wolf E, Hanhoff N, et al. Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort. Eur J Med Res 2009;14(7):277-83
   PubMed Web of Science ®Google Scholar
• Seng R, Goujard C, Desquilbet L, et al. Rapid CD4+ cell decrease after transient cART initiated during primary HIV infection (ANRS PRIMO and SEROCO cohorts). J Acquir Immune Defic Syndr 2008;49(3):251-8
   PubMed Web of Science ®Google Scholar
• Lampe FC, Porter K, Kaldor J, et al. Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study. Antivir Ther 2007;12(2):189-93
   PubMed Web of Science ®Google Scholar
• Fox J, Scriba TJ, Robinson N, et al. Human immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4+ T cell decline following short-course treatment at primary HIV-1 infection. Clin Exp Immunol 2008;152(3):532-7
   PubMed Web of Science ®Google Scholar
• Pantazis N, Touloumi G, Vanhems P, et al. The effect of antiretroviral treatment of different durations in primary HIV infection. AIDS 2008;22(18):2441-50
   PubMed Web of Science ®Google Scholar
• Lodi S, Meyer L, Kelleher AD, et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med 2012;172(16):1252-5
   PubMedGoogle Scholar
• Goujard C, Girault I, Rouzioux C, et al. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther 2012;17(6):1001-9
   PubMed Web of Science ®Google Scholar
• Grijsen ML, Steingrover R, Wit FW, et al. No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med 2012;9(3):e1001196
   PubMed Web of Science ®Google Scholar
• Hogan CM, Degruttola V, Sun X, et al. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis 2012;205(1):87-96
   PubMed Web of Science ®Google Scholar
• Grijsen M, Koster G, van VM, et al. Temporary antiretroviral treatment during primary HIV-1 infection has a positive impact on health-related quality of life: data from the Primo-SHM cohort study. HIV Med 2012;13(10):630-5
   PubMed Web of Science ®Google Scholar
• Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 2013;368(3):218-30
   PubMed Web of Science ®Google Scholar
• Mocroft A, Furrer HJ, Miro JM, et al. The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis 2013;57(7):1038-47
   PubMed Web of Science ®Google Scholar
• Hoen B, Fournier I, Lacabaratz C, et al. Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial. J Acquir Immune Defic Syndr 2005;40(3):307-16
   PubMed Web of Science ®Google Scholar
• Goujard C, Emilie D, Roussillon C, et al. Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial. AIDS 2012;26(15):1895-905
   PubMed Web of Science ®Google Scholar
• Emilie D, Burgard M, Lascoux-Combe C, et al. Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study. AIDS 2001;15(11):1435-7
   PubMed Web of Science ®Google Scholar
• Dybul M, Hidalgo B, Chun TW, et al. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J Infect Dis 2002;185(1):61-8
   PubMed Web of Science ®Google Scholar
• Volberding P, Demeter L, Bosch RJ, et al. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS 2009;23(15):1987-95
   PubMed Web of Science ®Google Scholar
• Ravot E, Tambussi G, Jessen H, et al. Effects of hydroxyurea on T cell count changes during primary HIV infection. AIDS 2000;14(5):619-22
   PubMed Web of Science ®Google Scholar
• Rizzardi GP, Harari A, Capiluppi B, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002;109(5):681-8
   PubMed Web of Science ®Google Scholar
• Markowitz M, Vaida F, Hare CB, et al. The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. J Infect Dis 2010;201(9):1298-302
   PubMed Web of Science ®Google Scholar
• Miro JM, Lopez-Dieguez M, Plana M, et al. Randomized clinical trial with immune-based therapy in patients with primary HIV-1 infection. Conference on Retroviruses and Opportunistic Infections (CROI); Montreol, Canada, 8-11 February 2009 (Abstract 531).
   Google Scholar
• Lewin SR, Murray JM, Solomon A, et al. Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection. J Acquir Immune Defic Syndr 2008;47(2):140-7
   PubMed Web of Science ®Google Scholar
• Persaud D, Gay H, Ziemniak C, et al. Absence of detectable hiv-1 viremia after treatment cessation in an infant. N Engl J Med 2013;369(19):1828-35
   PubMed Web of Science ®Google Scholar
• Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013;9(3):e1003211
   PubMed Web of Science ®Google Scholar
• Chéret A, Nembot G, Melard A, et al. Paradoxical impact of Maraviroc/Raltegravir added to HAART in acute HIV infection: ANRS 147 trial. Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA, 3-6 March 2014 (Abstract 549LB).
   Google Scholar
• Markowitz M, Evering TH, Garmon D, et al. A randomized open-label study of three- versus five-drug combination antiretroviral therapy in newly hiv-1 infected individuals. J Acquir Immune Defic Syndr 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Gianella S, von Wyl V, Fischer M, et al. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antivir Ther 2011;16(4):535-45
   PubMed Web of Science ®Google Scholar
• Ananworanich J, Vandergeeten C, Chomchey N, et al. Early ART Intervention Restricts the Seeding of the HIV Reservoir in Long-lived Central Memory CD4 T Cells. 20th Conference on Retroviruses and Opportunistic Infections; Atlanta, 3-6 March 2013 (Abstract 47).
   Google Scholar
• Tobin NH, Aldrovandi GM. Are infants unique in their ability to be “functionally cured” of HIV-1? Curr HIV/AIDS Rep 2014;11(1):1-10
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available from: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Last accessed 30 August 2013]
   Google Scholar
• Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012;308(4):387-402
   PubMed Web of Science ®Google Scholar
• The European AIDS Clinical Society (EACS. European Guidelines for treatment of HIV infected adults in Europe (v. 7.0 October 2013). Available from: www.eacsociety.org/Portals/0/Guidelines_Online_131014.pdf [Last accessed 23 October 2013]
   Google Scholar
• Panel de expertos de Gesida y Plan Nacional sobre el SIDA. Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2013). Enferm Infecc Microbiol Clin 2013; In press
   Web of Science ®Google Scholar
• Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012;13(Suppl 2):1-85
   Google Scholar
• WHO. Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection (Kuala Lumpur June 2013). Available from: www.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf [Last accessed 30 August 2013]
   Google Scholar
• Hatano H, Bacon O, Cohen S, et al. Lack of detectable HIV DNA in a PrEP study participant treated during "Hyperacute" HIV infection. Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA, USA, 3-6 March 2014 (Abstract 397LB).
   Google Scholar
• Schuetz A, Phuang-Ngern Y, Rerknimitr R, et al. Early ART initiation prevents disruption of the mucosal barrier and subsequent T-Cell activation. Conference on Retroviruses and Opportunistic Infections (CROI; Boston, MA, USA, 3-6 March 2014 (Abstract 77)
   Google Scholar
• Okoye A, Rohankhedkar M, Reyes M, et al. Early treatment in acute SIV infection limits the size and distribution of the viral reservoir. Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA, USA, 3-6 March 2014 (Abstract 136LB)
   Google Scholar